<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:a95055bb-481e-47df-bb9c-cc47602c31f4,g:33b2a1a6-8bdb-430d-86ad-59a97a5c4ede,d:9f76052f24f24c1da80d287080b6f05b--><html xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:link="http://www.xbrl.org/2003/linkbase" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>cstl-20220426</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i33edd732807b40afa7d8891a8a47549a_D20220426-20220426" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjlmNzYwNTJmMjRmMjRjMWRhODBkMjg3MDgwYjZmMDViL3NlYzo5Zjc2MDUyZjI0ZjI0YzFkYTgwZDI4NzA4MGI2ZjA1Yl80L2ZyYWc6MjJlOWIwMzRmN2E2NDU2ZGJhM2ZjMjFkNjAyMGMzOGEvdGFibGU6YzE0ZjA1YmUzODVlNDIxYzg4Y2Q2NGJlMDUzMTlmMDcvdGFibGVyYW5nZTpjMTRmMDViZTM4NWU0MjFjODhjZDY0YmUwNTMxOWYwN18wLTEtMS0xLTkyNjI2_bba423b4-27a3-4840-8857-3ff4abf8f739">0001447362</ix:nonNumeric><ix:nonNumeric contextRef="i33edd732807b40afa7d8891a8a47549a_D20220426-20220426" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjlmNzYwNTJmMjRmMjRjMWRhODBkMjg3MDgwYjZmMDViL3NlYzo5Zjc2MDUyZjI0ZjI0YzFkYTgwZDI4NzA4MGI2ZjA1Yl80L2ZyYWc6MjJlOWIwMzRmN2E2NDU2ZGJhM2ZjMjFkNjAyMGMzOGEvdGFibGU6YzE0ZjA1YmUzODVlNDIxYzg4Y2Q2NGJlMDUzMTlmMDcvdGFibGVyYW5nZTpjMTRmMDViZTM4NWU0MjFjODhjZDY0YmUwNTMxOWYwN18xLTEtMS0xLTkyNjI2_d80a64c5-2074-4410-802d-0307ee6ea930">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="cstl-20220426.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i33edd732807b40afa7d8891a8a47549a_D20220426-20220426"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-26</xbrli:startDate><xbrli:endDate>2022-04-26</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i9f76052f24f24c1da80d287080b6f05b_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i33edd732807b40afa7d8891a8a47549a_D20220426-20220426" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjlmNzYwNTJmMjRmMjRjMWRhODBkMjg3MDgwYjZmMDViL3NlYzo5Zjc2MDUyZjI0ZjI0YzFkYTgwZDI4NzA4MGI2ZjA1Yl8xL2ZyYWc6NzljMGI2YzQzNjkyNDg2YzgzYjE2ZTZjZmI0NjJkOTcvdGV4dHJlZ2lvbjo3OWMwYjZjNDM2OTI0ODZjODNiMTZlNmNmYjQ2MmQ5N180MDk3_21366740-7f06-4717-87fb-083c93fa37ff">8-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section 13 or 15(d)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">of the Securities Exchange Act of 1934</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="i33edd732807b40afa7d8891a8a47549a_D20220426-20220426" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjlmNzYwNTJmMjRmMjRjMWRhODBkMjg3MDgwYjZmMDViL3NlYzo5Zjc2MDUyZjI0ZjI0YzFkYTgwZDI4NzA4MGI2ZjA1Yl8xL2ZyYWc6NzljMGI2YzQzNjkyNDg2YzgzYjE2ZTZjZmI0NjJkOTcvdGV4dHJlZ2lvbjo3OWMwYjZjNDM2OTI0ODZjODNiMTZlNmNmYjQ2MmQ5N18yMjY_49255330-c818-439f-bf57-30b4a81871cc">April 26, 2022</ix:nonNumeric></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i33edd732807b40afa7d8891a8a47549a_D20220426-20220426" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjlmNzYwNTJmMjRmMjRjMWRhODBkMjg3MDgwYjZmMDViL3NlYzo5Zjc2MDUyZjI0ZjI0YzFkYTgwZDI4NzA4MGI2ZjA1Yl8xL2ZyYWc6NzljMGI2YzQzNjkyNDg2YzgzYjE2ZTZjZmI0NjJkOTcvdGV4dHJlZ2lvbjo3OWMwYjZjNDM2OTI0ODZjODNiMTZlNmNmYjQ2MmQ5N180MDk4_f0932510-3b6f-4105-9786-c4b9007c9abb">Castle Biosciences, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:22.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.812%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.812%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.814%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i33edd732807b40afa7d8891a8a47549a_D20220426-20220426" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjlmNzYwNTJmMjRmMjRjMWRhODBkMjg3MDgwYjZmMDViL3NlYzo5Zjc2MDUyZjI0ZjI0YzFkYTgwZDI4NzA4MGI2ZjA1Yl8xL2ZyYWc6NzljMGI2YzQzNjkyNDg2YzgzYjE2ZTZjZmI0NjJkOTcvdGFibGU6MTcyNWMyYjI0MTY1NGY3NjkyMzAyZDQ2NTY2MTM4MDQvdGFibGVyYW5nZToxNzI1YzJiMjQxNjU0Zjc2OTIzMDJkNDY1NjYxMzgwNF8xLTAtMS0xLTkyNjI2_45768c35-f1ef-4555-8718-be9b9dd64a43">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i33edd732807b40afa7d8891a8a47549a_D20220426-20220426" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjlmNzYwNTJmMjRmMjRjMWRhODBkMjg3MDgwYjZmMDViL3NlYzo5Zjc2MDUyZjI0ZjI0YzFkYTgwZDI4NzA4MGI2ZjA1Yl8xL2ZyYWc6NzljMGI2YzQzNjkyNDg2YzgzYjE2ZTZjZmI0NjJkOTcvdGFibGU6MTcyNWMyYjI0MTY1NGY3NjkyMzAyZDQ2NTY2MTM4MDQvdGFibGVyYW5nZToxNzI1YzJiMjQxNjU0Zjc2OTIzMDJkNDY1NjYxMzgwNF8xLTItMS0xLTkyNjI2_72664983-13b0-4b38-b401-6b2c6451cbcc">001-38984</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i33edd732807b40afa7d8891a8a47549a_D20220426-20220426" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjlmNzYwNTJmMjRmMjRjMWRhODBkMjg3MDgwYjZmMDViL3NlYzo5Zjc2MDUyZjI0ZjI0YzFkYTgwZDI4NzA4MGI2ZjA1Yl8xL2ZyYWc6NzljMGI2YzQzNjkyNDg2YzgzYjE2ZTZjZmI0NjJkOTcvdGFibGU6MTcyNWMyYjI0MTY1NGY3NjkyMzAyZDQ2NTY2MTM4MDQvdGFibGVyYW5nZToxNzI1YzJiMjQxNjU0Zjc2OTIzMDJkNDY1NjYxMzgwNF8xLTQtMS0xLTkyNjI2_7410de90-b053-4236-a3e9-1151fb4177e6">77-0701774</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction<br/>of incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Commission<br/>File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(IRS Employer<br/>Identification No.)</span></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:10.190%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.401%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.401%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.665%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i33edd732807b40afa7d8891a8a47549a_D20220426-20220426" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjlmNzYwNTJmMjRmMjRjMWRhODBkMjg3MDgwYjZmMDViL3NlYzo5Zjc2MDUyZjI0ZjI0YzFkYTgwZDI4NzA4MGI2ZjA1Yl8xL2ZyYWc6NzljMGI2YzQzNjkyNDg2YzgzYjE2ZTZjZmI0NjJkOTcvdGFibGU6MmI2ZWNlNzlkNWU0NDNhNmEzZWQ4YmY2OTNkNDNjNmUvdGFibGVyYW5nZToyYjZlY2U3OWQ1ZTQ0M2E2YTNlZDhiZjY5M2Q0M2M2ZV8wLTEtMS0xLTkyNjI2L3RleHRyZWdpb246YThmNjg2Y2NlZDQ1NDA0MGI5MTk2NjcxODhkYWQxY2JfNA_d268cc08-db14-4c03-a91f-113d9b4fa420">505 S. Friendswood Drive</ix:nonNumeric>, <ix:nonNumeric contextRef="i33edd732807b40afa7d8891a8a47549a_D20220426-20220426" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjlmNzYwNTJmMjRmMjRjMWRhODBkMjg3MDgwYjZmMDViL3NlYzo5Zjc2MDUyZjI0ZjI0YzFkYTgwZDI4NzA4MGI2ZjA1Yl8xL2ZyYWc6NzljMGI2YzQzNjkyNDg2YzgzYjE2ZTZjZmI0NjJkOTcvdGFibGU6MmI2ZWNlNzlkNWU0NDNhNmEzZWQ4YmY2OTNkNDNjNmUvdGFibGVyYW5nZToyYjZlY2U3OWQ1ZTQ0M2E2YTNlZDhiZjY5M2Q0M2M2ZV8wLTEtMS0xLTkyNjI2L3RleHRyZWdpb246YThmNjg2Y2NlZDQ1NDA0MGI5MTk2NjcxODhkYWQxY2JfOA_ce129c5d-c1b8-4f4c-bd6b-dcf2d21dc461">Suite 401</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i33edd732807b40afa7d8891a8a47549a_D20220426-20220426" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjlmNzYwNTJmMjRmMjRjMWRhODBkMjg3MDgwYjZmMDViL3NlYzo5Zjc2MDUyZjI0ZjI0YzFkYTgwZDI4NzA4MGI2ZjA1Yl8xL2ZyYWc6NzljMGI2YzQzNjkyNDg2YzgzYjE2ZTZjZmI0NjJkOTcvdGFibGU6MmI2ZWNlNzlkNWU0NDNhNmEzZWQ4YmY2OTNkNDNjNmUvdGFibGVyYW5nZToyYjZlY2U3OWQ1ZTQ0M2E2YTNlZDhiZjY5M2Q0M2M2ZV8wLTEtMS0xLTkyNjI2L3RleHRyZWdpb246YThmNjg2Y2NlZDQ1NDA0MGI5MTk2NjcxODhkYWQxY2JfMTE_b10e7e4b-331b-4e43-b25a-e7955819b7ce">Friendswood</ix:nonNumeric>, <ix:nonNumeric contextRef="i33edd732807b40afa7d8891a8a47549a_D20220426-20220426" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjlmNzYwNTJmMjRmMjRjMWRhODBkMjg3MDgwYjZmMDViL3NlYzo5Zjc2MDUyZjI0ZjI0YzFkYTgwZDI4NzA4MGI2ZjA1Yl8xL2ZyYWc6NzljMGI2YzQzNjkyNDg2YzgzYjE2ZTZjZmI0NjJkOTcvdGFibGU6MmI2ZWNlNzlkNWU0NDNhNmEzZWQ4YmY2OTNkNDNjNmUvdGFibGVyYW5nZToyYjZlY2U3OWQ1ZTQ0M2E2YTNlZDhiZjY5M2Q0M2M2ZV8wLTEtMS0xLTkyNjI2L3RleHRyZWdpb246YThmNjg2Y2NlZDQ1NDA0MGI5MTk2NjcxODhkYWQxY2JfMTU_eb81ced6-4939-404c-ae8a-4c79d8cfadfb">Texas</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i33edd732807b40afa7d8891a8a47549a_D20220426-20220426" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjlmNzYwNTJmMjRmMjRjMWRhODBkMjg3MDgwYjZmMDViL3NlYzo5Zjc2MDUyZjI0ZjI0YzFkYTgwZDI4NzA4MGI2ZjA1Yl8xL2ZyYWc6NzljMGI2YzQzNjkyNDg2YzgzYjE2ZTZjZmI0NjJkOTcvdGFibGU6MmI2ZWNlNzlkNWU0NDNhNmEzZWQ4YmY2OTNkNDNjNmUvdGFibGVyYW5nZToyYjZlY2U3OWQ1ZTQ0M2E2YTNlZDhiZjY5M2Q0M2M2ZV8wLTQtMS0xLTkyNjI2_e0f46e60-929d-4fe6-8ad0-3a5d632415d7">77546</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Zip Code)</span></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Registrant&#8217;s telephone number, including area code: (<ix:nonNumeric contextRef="i33edd732807b40afa7d8891a8a47549a_D20220426-20220426" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjlmNzYwNTJmMjRmMjRjMWRhODBkMjg3MDgwYjZmMDViL3NlYzo5Zjc2MDUyZjI0ZjI0YzFkYTgwZDI4NzA4MGI2ZjA1Yl8xL2ZyYWc6NzljMGI2YzQzNjkyNDg2YzgzYjE2ZTZjZmI0NjJkOTcvdGV4dHJlZ2lvbjo3OWMwYjZjNDM2OTI0ODZjODNiMTZlNmNmYjQ2MmQ5N180MTAz_3e77bb1b-b226-4fa7-bc9c-be7554bab4f7">866</ix:nonNumeric>) <ix:nonNumeric contextRef="i33edd732807b40afa7d8891a8a47549a_D20220426-20220426" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjlmNzYwNTJmMjRmMjRjMWRhODBkMjg3MDgwYjZmMDViL3NlYzo5Zjc2MDUyZjI0ZjI0YzFkYTgwZDI4NzA4MGI2ZjA1Yl8xL2ZyYWc6NzljMGI2YzQzNjkyNDg2YzgzYjE2ZTZjZmI0NjJkOTcvdGV4dHJlZ2lvbjo3OWMwYjZjNDM2OTI0ODZjODNiMTZlNmNmYjQ2MmQ5N180MTA0_9b245793-7e3b-49a0-a992-172ad1d8e550">788-9007</ix:nonNumeric></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Former name or former address, if changed since last report.)</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:&#160;</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i33edd732807b40afa7d8891a8a47549a_D20220426-20220426" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjlmNzYwNTJmMjRmMjRjMWRhODBkMjg3MDgwYjZmMDViL3NlYzo5Zjc2MDUyZjI0ZjI0YzFkYTgwZDI4NzA4MGI2ZjA1Yl8xL2ZyYWc6NzljMGI2YzQzNjkyNDg2YzgzYjE2ZTZjZmI0NjJkOTcvdGV4dHJlZ2lvbjo3OWMwYjZjNDM2OTI0ODZjODNiMTZlNmNmYjQ2MmQ5N180MTA2_caa1e57d-707c-4f51-836b-ba13d2929228">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i33edd732807b40afa7d8891a8a47549a_D20220426-20220426" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjlmNzYwNTJmMjRmMjRjMWRhODBkMjg3MDgwYjZmMDViL3NlYzo5Zjc2MDUyZjI0ZjI0YzFkYTgwZDI4NzA4MGI2ZjA1Yl8xL2ZyYWc6NzljMGI2YzQzNjkyNDg2YzgzYjE2ZTZjZmI0NjJkOTcvdGV4dHJlZ2lvbjo3OWMwYjZjNDM2OTI0ODZjODNiMTZlNmNmYjQ2MmQ5N180MTAw_9683a9dd-e3de-471d-b6cd-74c4da996c7d">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)&#160;</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i33edd732807b40afa7d8891a8a47549a_D20220426-20220426" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjlmNzYwNTJmMjRmMjRjMWRhODBkMjg3MDgwYjZmMDViL3NlYzo5Zjc2MDUyZjI0ZjI0YzFkYTgwZDI4NzA4MGI2ZjA1Yl8xL2ZyYWc6NzljMGI2YzQzNjkyNDg2YzgzYjE2ZTZjZmI0NjJkOTcvdGV4dHJlZ2lvbjo3OWMwYjZjNDM2OTI0ODZjODNiMTZlNmNmYjQ2MmQ5N180MTA4_02131799-620b-4fd3-852a-0aa8bd72abca">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i33edd732807b40afa7d8891a8a47549a_D20220426-20220426" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjlmNzYwNTJmMjRmMjRjMWRhODBkMjg3MDgwYjZmMDViL3NlYzo5Zjc2MDUyZjI0ZjI0YzFkYTgwZDI4NzA4MGI2ZjA1Yl8xL2ZyYWc6NzljMGI2YzQzNjkyNDg2YzgzYjE2ZTZjZmI0NjJkOTcvdGV4dHJlZ2lvbjo3OWMwYjZjNDM2OTI0ODZjODNiMTZlNmNmYjQ2MmQ5N180MTA5_6692a799-cb5a-4238-9526-e6896240b129">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Act:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:40.334%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.703%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.679%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i33edd732807b40afa7d8891a8a47549a_D20220426-20220426" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjlmNzYwNTJmMjRmMjRjMWRhODBkMjg3MDgwYjZmMDViL3NlYzo5Zjc2MDUyZjI0ZjI0YzFkYTgwZDI4NzA4MGI2ZjA1Yl8xL2ZyYWc6NzljMGI2YzQzNjkyNDg2YzgzYjE2ZTZjZmI0NjJkOTcvdGFibGU6MjlmMGY0Y2ZhYWY2NDRiN2E1YjkyNmFmMDFlZTFmMWEvdGFibGVyYW5nZToyOWYwZjRjZmFhZjY0NGI3YTViOTI2YWYwMWVlMWYxYV8xLTAtMS0xLTkyNjI2_52910b9d-60ae-42db-b924-8487209701c8">Common Stock, $0.001 par value per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i33edd732807b40afa7d8891a8a47549a_D20220426-20220426" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjlmNzYwNTJmMjRmMjRjMWRhODBkMjg3MDgwYjZmMDViL3NlYzo5Zjc2MDUyZjI0ZjI0YzFkYTgwZDI4NzA4MGI2ZjA1Yl8xL2ZyYWc6NzljMGI2YzQzNjkyNDg2YzgzYjE2ZTZjZmI0NjJkOTcvdGFibGU6MjlmMGY0Y2ZhYWY2NDRiN2E1YjkyNmFmMDFlZTFmMWEvdGFibGVyYW5nZToyOWYwZjRjZmFhZjY0NGI3YTViOTI2YWYwMWVlMWYxYV8xLTItMS0xLTkyNjI2_b07c9e74-c2e0-442a-b07c-805ee0dec80a">CSTL</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i33edd732807b40afa7d8891a8a47549a_D20220426-20220426" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjlmNzYwNTJmMjRmMjRjMWRhODBkMjg3MDgwYjZmMDViL3NlYzo5Zjc2MDUyZjI0ZjI0YzFkYTgwZDI4NzA4MGI2ZjA1Yl8xL2ZyYWc6NzljMGI2YzQzNjkyNDg2YzgzYjE2ZTZjZmI0NjJkOTcvdGFibGU6MjlmMGY0Y2ZhYWY2NDRiN2E1YjkyNmFmMDFlZTFmMWEvdGFibGVyYW5nZToyOWYwZjRjZmFhZjY0NGI3YTViOTI2YWYwMWVlMWYxYV8xLTQtMS0xLTkyNjI2_8f909b78-0196-46c6-a63d-ecf9620e0681">The Nasdaq Global Market</ix:nonNumeric></span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule 12b&#8211;2 of the Securities Exchange Act of 1934 (&#167; 240.12b&#8211;2 of this chapter).</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company&#160;&#160;<ix:nonNumeric contextRef="i33edd732807b40afa7d8891a8a47549a_D20220426-20220426" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjlmNzYwNTJmMjRmMjRjMWRhODBkMjg3MDgwYjZmMDViL3NlYzo5Zjc2MDUyZjI0ZjI0YzFkYTgwZDI4NzA4MGI2ZjA1Yl8xL2ZyYWc6NzljMGI2YzQzNjkyNDg2YzgzYjE2ZTZjZmI0NjJkOTcvdGV4dHJlZ2lvbjo3OWMwYjZjNDM2OTI0ODZjODNiMTZlNmNmYjQ2MmQ5N180MTAy_fb4fc2c9-3ab4-4c31-86d8-1612877384ea">&#9744;</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange&#160;Act.&#9744;&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3.02&#160;&#160;&#160;&#160;Unregistered Sales of Equity Securities.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 26, 2022, Castle Biosciences, Inc. (the &#8220;Company&#8221;) completed its previously announced acquisition of AltheaDx, Inc. (&#8220;AltheaDx&#8221;). A</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">t closing, $65.0 million in initial consideration was payable by the Company to AltheaDx securityholders, which consisted of $32.5 million in cash, subject to adjustments for cash, debt, transaction expenses and working capital, and $32.5 million in shares of the Company&#8217;s common stock. T</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he Company issued 763,887 shares of its common stock to satisfy the portion of the closing consideration payable in shares of the Company&#8217;s common stock. The </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">number of shares issued at closing was based on a price per share equal to the volume-weighted-average price of the Company&#8217;s common stock for the 20 trading days immediately preceding the date of the merger agreement governing the acquisition. A portion of the shares issued at closing is being held in escrow to secure indemnification claims of the Company, if any.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition, the Company has also agreed to pay up to an additional $75.0 million based on the achievement of certain milestones achievable through December 31, 2024. Upon achievement of the relevant milestones, each milestone payment will be paid 50% in cash and 50% in the Company&#8217;s common stock, with such common stock valued at the volume-weighted-average price of the Company&#8217;s common stock for the 20 trading days as of the applicable milestone determination date. The maximum number of shares of the Company&#8217;s common stock issuable to AltheaDx securityholders in connection with the acquisition may not exceed 1,271,718 shares, and therefore, a maximum of 507,831 additional shares of common stock remain issuable with respect to the milestone payments. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The shares of common stock of the Company that were issued, and that may be issued, as consideration for the acquisition are not being registered under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and are being offered pursuant to the exemption provided in Section 4(a)(2) under the Securities Act and Rule 506 of Regulation D thereunder. The Company has agreed to file a resale registration statement covering the shares of the Company&#8217;s common stock issuable in connection with the acquisition within 40 days of closing, subject to the receipt of certain information from AltheaDx and its securityholders and certain specified exceptions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SIGNATURES</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.<br/></span></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:49.926%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.295%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.479%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CASTLE BIOSCIENCES, INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Frank Stokes</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Frank Stokes</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: May 2, 2022</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
[{"type": "8-K", "sequence": "1", "filename": "cstl-20220426.htm", "description": "8-K", "secsgml_size_bytes": 36610}]
{"company-data": {"conformed-name": "CASTLE BIOSCIENCES INC", "cik": "0001447362", "assigned-sic": "8071", "irs-number": "770701774", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-38984", "film-number": "22882299"}, "business-address": {"street1": "505 S FRIENDSWOOD DRIVE", "street2": "SUITE 401", "city": "FRIENDSWOOD", "state": "TX", "zip": "77546", "phone": "866-788-9007"}, "mail-address": {"street1": "505 S FRIENDSWOOD DRIVE", "street2": "SUITE 401", "city": "FRIENDSWOOD", "state": "TX", "zip": "77546"}}
cstl-20220426
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
April 26, 2022
Castle Biosciences, Inc.
(Exact name of registrant as specified in its charter)
Delaware
001-38984
77-0701774
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
505 S. Friendswood Drive
,
Suite 401
Friendswood
,
Texas
77546
(Address of principal executive offices)
(Zip Code)
Registrant's telephone number, including area code: (
866
)
788-9007
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $0.001 par value per share
CSTL
The Nasdaq Global Market
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b–2 of the Securities Exchange Act of 1934 (§ 240.12b–2 of this chapter).
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐
Item 3.02    Unregistered Sales of Equity Securities.
On April 26, 2022, Castle Biosciences, Inc. (the "Company") completed its previously announced acquisition of AltheaDx, Inc. ("AltheaDx"). A
t closing, $65.0 million in initial consideration was payable by the Company to AltheaDx securityholders, which consisted of $32.5 million in cash, subject to adjustments for cash, debt, transaction expenses and working capital, and $32.5 million in shares of the Company's common stock. T
he Company issued 763,887 shares of its common stock to satisfy the portion of the closing consideration payable in shares of the Company's common stock. The
number of shares issued at closing was based on a price per share equal to the volume-weighted-average price of the Company's common stock for the 20 trading days immediately preceding the date of the merger agreement governing the acquisition. A portion of the shares issued at closing is being held in escrow to secure indemnification claims of the Company, if any.
In connection with the acquisition, the Company has also agreed to pay up to an additional $75.0 million based on the achievement of certain milestones achievable through December 31, 2024. Upon achievement of the relevant milestones, each milestone payment will be paid 50% in cash and 50% in the Company's common stock, with such common stock valued at the volume-weighted-average price of the Company's common stock for the 20 trading days as of the applicable milestone determination date. The maximum number of shares of the Company's common stock issuable to AltheaDx securityholders in connection with the acquisition may not exceed 1,271,718 shares, and therefore, a maximum of 507,831 additional shares of common stock remain issuable with respect to the milestone payments.
The shares of common stock of the Company that were issued, and that may be issued, as consideration for the acquisition are not being registered under the Securities Act of 1933, as amended (the "Securities Act"), and are being offered pursuant to the exemption provided in Section 4(a)(2) under the Securities Act and Rule 506 of Regulation D thereunder. The Company has agreed to file a resale registration statement covering the shares of the Company's common stock issuable in connection with the acquisition within 40 days of closing, subject to the receipt of certain information from AltheaDx and its securityholders and certain specified exceptions.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
CASTLE BIOSCIENCES, INC.
By:
/s/ Frank Stokes
Frank Stokes
Chief Financial Officer
Date: May 2, 2022